Markets:

Overview

News

Currencies

International

Treasuries

Madrigal Pharmaceuticals, Inc. - Common Stock (NQ:MDGL)

518.22 +6.25 (+1.22%)

Streaming Delayed Price Updated: 10:53 AM EDT, Aug 25, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Madrigal Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Madrigal’s Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands ↗

August 15, 2026

Madrigal Pharmaceuticals (NASDAQ:MDGL) said Rezdiffra continued to post strong commercial growth in the second quarter of 2026, while the company expanded its development pipeline around the MASH...

Via MarketBeat

Madrigal Pharmaceuticals Q2 Earnings Call Highlights ↗

July 30, 2026

Madrigal Pharmaceuticals (NASDAQ:MDGL) reported second-quarter 2026 net sales of $364.3 million for Rezdiffra, up 71% from a year earlier, as the company continued to expand the number of patients...

Via MarketBeat

Topics Earnings

Madrigal Pharmaceuticals (NASDAQ:MDGL) Posts Q2 Beat Yet Shares Slide on Rezdiffra Ramp Worries ↗

July 30, 2026

Via Chartmill

3 Under-the-Radar Stocks to Buy and Hold ↗

July 10, 2026

Sometimes, little-known stocks are worth buying.

Via The Motley Fool

Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Dip Despite Q1 2026 Earnings Beat and 127% Rezdiffra Revenue Growth ↗

May 06, 2026

Via Chartmill

Topics Earnings

Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) Reports Q4 2025 Revenue Beat and Significant EPS Miss ↗

February 19, 2026

Via Chartmill

Madrigal Doubles Down On MASH With A $4.4 Billion Licensing Deal With China’s Ribo ↗

February 11, 2026

Via Stocktwits

3 Under-the-Radar Stocks to Buy and Hold for a Decade ↗

June 16, 2026

All three could become highly prominent biotech companies within 10 years.

Via The Motley Fool

Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800% ↗

May 29, 2026

This clinical-stage biotech develops targeted oral therapies for RAS/MAPK-driven cancers, with all assets currently in development.

Via The Motley Fool

Topics Regulatory Compliance

Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More ↗

May 29, 2026

This biotechnology firm advances targeted cancer therapies, leveraging genetic insights and strategic partnerships in oncology.

Via The Motley Fool

Arrowhead (ARWR) Q2 2026 Earnings Transcript ↗

May 08, 2026

Arrowhead (ARWR) Q2 2026 Earnings Transcript

Via The Motley Fool

Madrigal (MDGL) Q1 2026 Earnings Transcript ↗

May 06, 2026

Madrigal (MDGL) Q1 2026 Earnings Transcript

Via The Motley Fool

3 Under-the-Radar Healthcare Stocks Worth Adding to Your Watchlist ↗

April 16, 2026

These companies boast significant upside potential.

Via The Motley Fool

Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now ↗

March 25, 2026

The next 10 months might be challenging for this biotech.

Via The Motley Fool

This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story ↗

March 21, 2026

This biotech firm develops therapies for rare, complement-driven diseases, with a focus on autoimmune and inflammatory conditions.

Via The Motley Fool

Topics Regulatory Compliance

This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch ↗

March 21, 2026

Cogent Biosciences develops targeted therapies for genetically defined diseases, focusing on precision medicine for rare cancers.

Via The Motley Fool

Topics Regulatory Compliance

This Specialized Heart Monitor Maker Just Caught the Eye of a Major Healthcare Fund ↗

March 20, 2026

RTW Investments loads up on iRhythm Holdings with 1.18M Shares Worth $210 million. iRhythm delivers wearable cardiac monitoring and analytics solutions to healthcare providers and at-risk patients.

Via The Motley Fool

Topics Regulatory Compliance

2 Under-the-Radar Stocks to Buy and Hold ↗

March 10, 2026

These biotechs are slowly making a name for themselves.

Via The Motley Fool

Madrigal (MDGL) Q4 2025 Earnings Call Transcript ↗

February 23, 2026

Madrigal (MDGL) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings Intellectual Property

Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year ↗

February 23, 2026

Praxis Precision Medicines develops therapies for neurological and psychiatric disorders, aiming to address unmet needs in the CNS market.

Via The Motley Fool

Topics Regulatory Compliance

This Fund Bet Nearly $40 Million on GRAIL Last Quarter. The Stock Just Plunged Over 50% ↗

February 23, 2026

GRAIL develops advanced cancer detection technologies, serving healthcare providers and individuals seeking early diagnostic solutions.

Via The Motley Fool

Topics Regulatory Compliance

Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash ↗

February 17, 2026

Agios Pharmaceuticals targets rare blood disorders with a marketed anemia drug and a focused clinical-stage pipeline.

Via The Motley Fool

Topics Regulatory Compliance

Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million ↗

February 17, 2026

This biotech firm develops precision therapies targeting rare genetic diseases, with a lead candidate focused on oncology indications.

Via The Motley Fool

Topics Regulatory Compliance

Structure Therapeutics Stock Up 187% in One Year as Fund Trims $8 Million From Stake ↗

February 17, 2026

Structure Therapeutics develops oral therapies for chronic diseases, using a proprietary platform to target G-protein-coupled receptors.

Via The Motley Fool

Kymera Therapeutics Stock Up 120% in 1 Year as Fund Adds $3 Million More ↗

February 17, 2026

Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing multiple clinical-stage programs.

Via The Motley Fool

Why Madrigal Pharmaceuticals Stock Slumped on Tuesday ↗

January 06, 2026

The stock has had quite the run following Rezdiffra's 2024 approval by the FDA.

Via The Motley Fool

Ignore Nektar Therapeutics Stock in 2026 and Load Up on This One Instead ↗

January 05, 2026

There is a key difference between these two biotechs.

Via The Motley Fool

Topics Bankruptcy

2 Tailwinds Behind Novo Nordisk Stock Heading Into 2026 ↗

January 03, 2026

The pharmaceutical leader looks poised to stop the bleeding.

Via The Motley Fool

2 Predictions for Novo Nordisk in 2026 ↗

December 14, 2025

The company's worst days might be behind it.

Via The Motley Fool

2 Stocks Up Over 600% in the Past 3 Years With More Room to Run ↗

December 09, 2025

They haven't peaked yet.

Via The Motley Fool

Topics Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.